ARTIFICIAL BACTERIOPHAGE BASED ON CARBON NANOSTRUCTURES FOR SUPPLYING MEDICAMENTS

Abstract

The invention relates to an artificial bacteriophage for supplying medicaments, nutrients, proteins, DNA/RNA or other type of molecules to bacteria and/or diseased cells, directly to the cytoplasm, passing through the cell membrane thereof, through a pore of said membrane. The artificial bacteriophage is based on carbon nanostructures and comprises a nanocontainer for medicaments, a channel for transporting medicaments and a tip together with an array of linker proteins and protein receptors.

Claims

1. Artificial bacteriophage (1) based on carbon nanostructures, characterized because it comprises the following structural components: a) A medication nanocontainer (2) with an icosahedral shape designed through a Fullerene carbon structure b) A drug transport channel (3) designed from a single-wall carbon nanotube (SWCNT) c) A PINNACLE (4) conformed by a SWCNT or a boron nitride SWCNT heterostructure along with a binding protein array (linkers) (4b) and protein receptors (4c).

2. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 1, characterized because the medication nanocontainer (2) has a diameter between 3 and 10 nm.

3. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 1, characterized because the drug transport channel (3) has a diameter between 2 and 3.5 nm, and a length between 10 and 20 nm; can be de armchair-type or zigzag, and have different chiralities.

4. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 1, characterized because the pinnacle (4) that has the binding protein array (4b) and protein receptors (4c) has a diameter between 2 and 3.5 nm, and an average length of 5 nm.

5. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 1, characterized because it has a pinnacle (4) that consists of un SWCNT (4a) and a binding protein array (4b) and protein receptors (4c).

6. Artificial bacteriophage (1) based on carbon nanostructures, according to dependent claim 5, characterized because it has a ring of binding proteins (4.1b) 0.8 nm long and 0.3 nm wide, approximately.

7. Artificial bacteriophage (1) based on carbon nanostructures, according to dependent claim 5, characterized because the set of binding proteins (4c) is 1.2 nm long and 0.3 nm thick, approximately.

8. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 1, characterized because it has a pinnacle (4) that consists of a boron nitride SWCNT heterostructure (6a) divided into three segments (6b, 6c, 6d), and a binding protein array (4b) and protein receptors (4c).

9. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 8, characterized because a ring of binding proteins (4.1b) is 0.8 nm long and 0.3 nm wide, approximately.

10. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 8, characterized because each segment (6b, 6c, 6d) of the boron nitride SWCNT heterostructure (6a) is 1.0 nm thick.

11. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 8, characterized because the set of binding proteins (4b) is 0.8 nm long and the protein receptors (5) are 1.2 nm long and 0.3 nm thick.

12. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 1, characterized because it has a pinnacle (4) that consists of a boron nitride protein—SWCNT heterostructure (7a), and a binding protein array (4b) and protein receptors (4c), where the binding proteins are covalently functionalized outside the boron nitride SWCNT heterostructure.

13. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 12, characterized because each segment (7b, 7c, 7d) of the boron nitride SWCNT heterostructure (6a) is 1.0 nm thick.

14. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 12, characterized because the set of binding proteins (4b) is 0.8 nm long and the protein receptors (5) are 1.2 nm long and 0.3 nm thick.

15. Artificial bacteriophage (1) based on carbon nanostructures, according to claim 1, characterized because a procedure for drug delivery through the artificial bacteriophage (1) comprises the stages of: a) location and adhesion to the proteins around the membrane pore of the sick cell or bacteria; b) applies a stimulus (voltage) or self-stimulus (ligand) appropriate to activate drug release; c) supplies the medication through osmotic pressure gradient or ionic potential gradient.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0027] FIG. 1. Shows an artificial bacteriophage (1) based on carbon nanostructures along with its characteristic construction techniques.

[0028] FIG. 1A. Shows an artificial bacteriophage (1) along with its dimensions designated under representation in letters.

[0029] FIG. 2. Shows different pinnacle models (4) that are part of an artificial bacteriophage (1) along with its respective hetero-structures and binding protein arrays (4b) and protein receptors (4c), as well as with its characteristic construction techniques.

[0030] FIG. 2A. Shows an artificial bacteriophage (1) with the first pinnacle model (4) along with its respective binding protein array (4a) and protein receptors (5), as well as with its characteristic construction techniques and dimensions designated under representation in letters.

[0031] FIG. 2B. Shows an artificial bacteriophage (1) with the second pinnacle model (4) along with its respective binding protein array (4b) and protein receptors (4c), as well as with its characteristic construction techniques and dimensions designated under representation in letters.

[0032] FIG. 2C. Shows an artificial bacteriophage (1) with the third pinnacle model (4) along with its respective binding protein array (4b) and protein receptors (4c), as well as with its characteristic construction techniques and dimensions designated under representation in letters.

[0033] FIG. 3. Presents a graphic of several simulation images of an artificial bacteriophage (1), showing drug transport in several environments through the transport channel (3) elaborated from a single-wall carbon nanotube (SWCNT). In vacuum environment, it shows image a) methotrexate and b) geldanamycin. In air environment, it shows image c) geldanamycin. In water environment, it shows image d) gemcitabine and e) doxorubicin.